Medication for behaviour problems associated with learning disabilities

Psychiatry

Volumn 5, Issue 10, 2006, Pages 368-371

  Deb, Shoumitro ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

behaviour problems; learning disability; psychotropic medication

Indexed keywords

AMISULPRIDE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CHLORPROMAZINE; CLOMIPRAMINE; CLOZAPINE; HALOPERIDOL; LITHIUM; MOOD STABILIZER; NALOXONE; NALTREXONE; NEUROLEPTIC AGENT; OLANZAPINE; OPIATE ANTAGONIST; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTINDOLE; THIORIDAZINE; UNINDEXED DRUG; VITAMIN; ZOTEPINE;

AGRANULOCYTOSIS; AKATHISIA; ALCOHOL INTOLERANCE; ATTENTION DEFICIT DISORDER; AUTISM; BEHAVIOR DISORDER; BRADYCARDIA; CLINICAL TRIAL; COGNITIVE DEFECT; DIET; DRUG EFFICACY; DRUG MONITORING; DYSTONIA; GLUCOSE INTOLERANCE; HEALTH CARE PLANNING; HEALTH PROGRAM; HEART BLOCK; HEART DISEASE; HUMAN; HYPERPROLACTINEMIA; HYPOTENSION; LEARNING DISORDER; MENTAL PATIENT; METABOLIC DISORDER; NEUROLEPTIC MALIGNANT SYNDROME; PARKINSONISM; PATIENT CARE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; TREATMENT INDICATION; VITAMIN SUPPLEMENTATION; WEIGHT GAIN; WITHDRAWAL SYNDROME;

EID: 33845351158     PISSN: 14761793     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.mppsy.2006.07.006     Document Type: Review

References (18)

1. Deb S., Thomas M., and Bright C. Mental disorder in adults with intellectual disability. I: prevalence of functional psychiatric illness among a community-based population aged between 16 and 64 years. J Intellect Disabil Res 45 (2001) 495-505
2. Deb S., Thomas M., and Bright C. Mental disorder in adults with intellectual disability. 2: the rate of behaviour disorders among a community-based population aged 16 and 64 years. J Intellect Disabil Res 45 (2001) 506-514
3. Smith S., Branford D., Collacott R., Cooper S.A., and McGrother C. Prevalence and cluster typology of maladaptive behaviours in a geographically defined population of adults with learning disability. Br J Psychiatry 169 (1996) 219-227
4. Deb S., Matthews T., Holt G., Bouras N., eds. Practice guidelines for the assessment and diagnosis of mental health problems in adults who have intellectual disability. European Association for Mental Health in Mental Retardation (EAMHMR). London: Pavilion Press, 2001. Available at: http://www.estiacentre.org
5. Deb S. Epidemiology and treatment of epilepsy in patients who are mentally retarded. CNS Drugs 13 (2000) 117-128
6. Deb S., and Fraser W. The use of psychotropic medication in people with learning disability: towards rational prescribing. Hum Psychopharmacol 9 (1994) 259-272
7. Clarke D.J., Kelley S., Thinn K., and Corbett J.A. Psychotropic drugs and mental retardation: I. Disabilities and the prescription of drugs for behaviour and for epilepsy in three residential settings. J Ment Defic Res 34 (1990) 385-395
8. Reiss S., and Aman M.G. The international consensus handbook: psychotropic medications and developmental disabilities (1998), American Association on Mental Retardation, Washington, DC
9. Santosh P.J., and Baird G. Psychopharmacology in children and adults with intellectual disability. Lancet 354 (1999) 231-240
10. Deb S., and Weston S.N. Psychiatric illness and mental retardation. Curr Opin Psychiatry 13 (2000) 497-505
11. Aman M.G., Alvarez N., Benefield W., et al. Expert consensus guidelines for the treatment of psychiatric and behavioral problems in mental retardation. Am J Ment Retard 105 (2000) 159-228
12. Deb S., and Joyce J. Psychiatric illness and behavioural problems in adults with learning disability and epilepsy. Behav Neurol 11 (1999) 125-129
13. Brylewski J., Duggan L. Antipsychotic medication for challenging behaviour in people with learning disability. The Cochrane Database of Systematic Reviews 2004, Issue 3. art. no.: CD000377. DOI: 10.1002/14651858.CD000377.pub2
14. Ahmed Z., Fraser W., Kerr M.P., et al. Reducing antipsychotic medication in people with a learning disability. Br J Psychiatry 178 (2000) 42-46
15. Branford D. Factors associated with the successful or unsuccessful withdrawal of antipsychotic drug therapy prescribed for people with learning disabilities. J Intellect Disabil Res 40 (1996) 322-329
16. Department of Health. Valuing people: toward person centred approaches (2002), Department of Health, London
17. Scottish Executive. The same as you: a review of services for people with learning disabilities. Edinburgh: Scottish Executive, n.d. Available at: http://www.scotland.gov.uk
18. Deb S., Clarke D., Unwin G. Using medication to manage behaviour problems among adults with a learning disability: quick reference guide. Birmingham: Univerisity of Birmingham, Royal College of Psychiatrists, The Royal Society of Mencap, London. Available at: http://www.LD-medication.bham.ac.uk